P684: PHASE 1 STUDY OF LP-108, A SELECTIVE BCL-2 INHIBITOR, IN PATIENTS WITH RELAPSED OR REFRACTORY B-CELL NON-HODGKIN LYMPHOMA

• W. Xu,
• R. Feng,
• L. Wang,
• Y. Song,
• H. Zhu,
• L. Fan,
• X. Guo,
• X. Wei,
• N. Lin,
• C. Xu,
• Z. Wang,
• X. Xiao,
• Y. Shen,
• Y. Chen,
• Y. Chen,
• F. Tan,
• S. P. Anthony,
• J. Li

Affiliations

W. Xu

1 Department of Hematology, The First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Nanjing

R. Feng

2 Department of Hematology, Nanfang Hospital of Southern Medical University, Guangzhou

L. Wang

1 Department of Hematology, The First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Nanjing

Y. Song

3 Department of Lymphoma, Beijing Cancer Hospital, Beijing

H. Zhu

1 Department of Hematology, The First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Nanjing

L. Fan

1 Department of Hematology, The First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Nanjing

X. Guo

2 Department of Hematology, Nanfang Hospital of Southern Medical University, Guangzhou

X. Wei

2 Department of Hematology, Nanfang Hospital of Southern Medical University, Guangzhou

N. Lin

3 Department of Lymphoma, Beijing Cancer Hospital, Beijing

C. Xu

4 Phase I Unit, Nanfang Hospital of Southern Medical University

Z. Wang

5 Department of Clinical Development, Guangzhou Lupeng Pharmaceutical Co., Ltd., Guangzhou, China

X. Xiao

5 Department of Clinical Development, Guangzhou Lupeng Pharmaceutical Co., Ltd., Guangzhou, China

Y. Shen

5 Department of Clinical Development, Guangzhou Lupeng Pharmaceutical Co., Ltd., Guangzhou, China

Y. Chen

6 Department of Clinical Development, Newave Pharmaceutical Inc., Pleasanton, United States of America

Y. Chen

6 Department of Clinical Development, Newave Pharmaceutical Inc., Pleasanton, United States of America

F. Tan

5 Department of Clinical Development, Guangzhou Lupeng Pharmaceutical Co., Ltd., Guangzhou, China

S. P. Anthony

6 Department of Clinical Development, Newave Pharmaceutical Inc., Pleasanton, United States of America

J. Li

1 Department of Hematology, The First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Nanjing